APONTIS PHARMA announces launch of new Single Pill for more efficient treatment of hypertension and hyperlipidemia

Monheim am Rhein, 14 September 2021. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, today announced the signing of a new in-licensing agreement for a new Single Pill. The market launch in Germany is planned for early 2022.

The medication addresses patients who are simultaneously affected by hypertension (high blood pressure) and hyperlipidemia (disorder of lipid metabolism). The objective is to increase adherence by combining two active ingredients in just one pill and thus achieve a more efficient therapy for patients.

The success of the Single Pill therapy strategy was proven by the START study conducted in 2019. It showed that patients benefited from a Single Pill compared to a multi-pill regime with the same substances. Instead of taking several individual preparations, treatment with the combination of substances in a Single Pill, which combines up to three active substances, promises a much higher adherence to therapy. Consequently, medications are taken more reliably when the dosage form is limited to one pill.

APONTIS PHARMA is also pursuing this proven approach with its latest product and is offering a large and steadily increasing number of patients treatment perspective that meets their needs. Overall, APONTIS PHARMA is addressing a group of around half a million people in Germany who, in the case of hypertension and hyperlipidemia, have so far been taking a loose combination of these two substances. Accordingly, APONTIS PHARMA and the new Single Pill are opening up a promising market environment.

"As the Single Pill Company, our objective is to ensure the therapeutic success of patients through highly effective medications and to reduce costs for insurers to a minimum. We have many years of expertise in the so-called diseases of civilization and are now already launching the ninth Single Pill on the market. Hence, we are well on the way to achieving our ambitious goal of at least 20 Single Pill products by 2026," says Karlheinz Gast, Chief Executive Officer of APONTIS PHARMA AG.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three patent-free active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Deutschland
apontis-pharma.de/

APONTIS PHARMA Press Contact

CROSS ALLIANCE
Sven Pauly
Sara Pinto
ir@apontis-pharma.de
T: +49 89 125 09 0330